THE CASE
A 57-year-old, white man was diagnosed with grade IV glioblastoma multiforme (GBM) in March 2005. He was enrolled in an adoptive cellular gene immunotherapy (ACGT) clinical trial 5 months after diagnosis (BB-IND 10109, approved by the FDA). After primary therapy was completed (a gross total resection, 60 Gy involvedfield radiotherapy with concurrent temozolomide at 75 mg/m 2 daily, then adjuvant temozolomide at 150 mg/m 2 daily for 5 days, every 4 weeks) the patient provided his informed consent to leukapheresis, and the cells isolated by this technique were used to culture T cells.
The patient was in good health until December 2004 when he experienced his first grand mal seizure. The initial workup failed to identify a causative etiology. Brain imaging with contrast MRI revealed a 2 cm enhancing, right-occipital, extra-axial mass consistent with a meningioma.
S u M M a rY
Background A 57-year-old man had been diagnosed with grade IV glioblastoma multiforme and was enrolled in a trial of adoptive cellular immunotherapy. The trial involved infusion of ex vivo expanded autologous cytolytic CD8 + T cells (CTLs), genetically engineered to express the interleukin 13 zetakine gene (which encodes a receptor protein that targets these T cells to tumor cells) and the herpes simplex virus 1 thymidine kinase (HSV1 tk) suicide gene, and PET imaging reporter gene.
Investigations MRI, whole-body and brain PET scan with 18 F-radiolabelled 9-[4-fluoro-3-(hydroxymethyl)butyl]guanine ( 18 F-FHBG) to detect CTLs that express HSV1 tk, and safety monitoring after injection of 18 F-FHBG. Diagnosis 
MRI detected grade III-IV glioblastoma multiforme plus two tumors recurrences that developed after resection of the initial tumor.
Management Surgical resection of primary glioblastoma tumor, enrollment in CTL therapy trial, reresection of glioma recurrences, infusion of approximately 1 × 10 9 CTLs into the site of tumor reresection, and 18 F-FHBG PET scan to detect infused CTLs. The patient was diagnosed as having an idiopathic seizure disorder, and was started on oral lamotrigine 250 mg twice daily. He experienced further seizures and in March 2005 complained of headaches with physical exertion. MRI revealed a new, small, enhancing mass in the right parietal occipital cortex and the patient was referred for neurosurgical evaluation. Craniotomy and resection was recommended, from which the patient recovered without new neurological deficits. A follow-up MRI showed features consistent with gross total resection and histopathologic evaluation led to a diagnosis of GBM. The patient was referred for radiotherapy with concurrent daily temozolomide. The patient received a 6 week course of multifield, fractionated, intensity-modulated (6 MV) radiotherapy, in which an initial wide field received 50 Gy and the involved region received 60 Gy. The patient was treated with 75 mg/m 2 daily doses of temozolomide during radiation treatment, followed by 6 months of adjuvant temozolomide (200 mg/m 2 daily for 5 days every 4 weeks).
At 9 months after the initial diagnosis of GBM a recurrent tumor adjacent to the resection cavity was detected by MRI. The recurrent tumor was resected and a Rickham reservoir was inserted to allow infusion of genetically engineered autologous CD8 + cytolytic T cells (CTLs).
DISCUSSION OF CTL INFUSION TECHNIQUE
T cells were isolated from the patient's peripheral blood mononuclear cells and electroporated, with a plasmid construct that encoded genes for interleukin (IL)-13 zetakine, hygromycin and herpes simplex virus 1 thymidine kinase (HSV1 tk) under the transcriptional control of a modified human elongation factor-1α (EF1α) promoter and the cytomegalovirus immediate or early promoter, respectively.
Hygromycin-resistant CTLs were first cloned and then expanded using the rapid expansion method (T cells are activated with muromonab in combination with irradiated feeder cells and propagated in 50 U/ml recombinant human IL-2) to numbers in excess of 1 × 10 9 and the isolated cells were cryopreserved. After diagnosis of disease relapse, 9 months after initial diagnosis, cryopreserved cells were thawed, expanded and formulated for intracranial infusion (see Supplementary Data online for quality assurance of infused CTLs). These cells were infused on Mondays, Wednesdays and Fridays over a period of 5 weeks, with a break on week 3 (see Supplementary Timeline online). The patient was initially given an infusion of 1 × 10 7 CTLs. As this dose was well tolerated, subsequent infusions were increased to 1 × 10 8 (1) is evident in the left corner of his brain and a new, nonresected tumor in the center (2), near the corpus callosum. The infused cells had localized at the site of tumor 1 and trafficked to tumor 2. 18 F-FHBG activity at both sites is higher than background activity. Background 18 F-FHBG activity is low within the central nervous system because of the probe's inability to cross the bloodbrain barrier; however, activity can be observed in the meninges. The tumor 1: meninges and tumor 2:meninges 18 F-FHBG activity ratios in this patient were 1.75 and 1.57, respectively. The average resected tumor site:meninges and intact tumor site:meninges 18 F-FHBG activity ratios in control patients were 0.86 and 0.44, respectively. Abbreviations: SUV, standardized uptake value. of the schedule the patient had received a cumulative dose of approximately 1 × 10 9 genetically engineered autologous CTLs. During the patient's initial course of treatment for GBM an enhancing lesion was identified in the posterior corpus callosum in the contralateral hemisphere. This lesion was confirmed upon biopsy as GBM and the patient received additional focal CT-guided intensity-modulated radiation therapy (45 Gy given in 1.5 Gy daily fractions over 6 weeks), bevacizumab 5 mg/kg every 2 weeks and carmustine 200 mg/m 2 every 6 weeks over 5 months. Upon further progression, as assessed by contrast-enhanced MRI, the patient received a series of intralesional T-cell infusions. MRI revealed a substantial tumor regression 14 weeks thereafter. The patient survived for 14 months from the time of initial recurrence. During T-cell therapy no serious, unexpected adverse events were encountered; the patient's major complaint was, as expected, intermittent headache.
DISCUSSION OF IMAGING WITH 18 F-FHBG
The patient had a PET scan to detect the engineered CTLs within his body three days after completion of a 5-week cycle of CTL infusions. The CTLs were imaged with the PET reporter probe, 18 F-radiolabelled 9-[4-fluoro-3-(hydroxy methyl)butyl]guanine ( 18 F-FHBG). 1 18 F-FHBG is approved by the FDA as an investigational new drug (IND #61,880) for use in PET imaging at UCLA and Stanford University nuclear medicine clinics.
The patient gave informed consent and underwent assessment of his cognitive function using the mini-mental state examination. Urine and blood samples were collected for baseline biochemical analysis. The patient's baseline vital signs, including temperature, heart rate and electrical activity, blood pressure, blood oxygen saturation and respiratory rate were monitored. The electrocardiography data were recorded approximately every 15 min (up to 2 h) after 18 F-FHBG injection, and the other vital signs were recorded at approximately 5, 10, 15, 30, 60 and 120 min after 18 F-FHBG injection. All of these assessments were repeated 1 day and 1 week after the imaging session. Blood and urine were collected for laboratory tests during the follow-up assessments (these measurements are provided in Supplementary Data Set 1 online) . Finally, the patient underwent another mini-mental state examination a week after 18 F-FHBG injection to rule out any effect of treatment on cognitive functions; the patient's score was 25 on both baseline and post-treatment examinations.
The patient received an injection of 254.62 MBq 18 F-FHBG, which was within the FDA-approved dose limits. Approximately 2¼ h after the injection, a whole-body PET emission scan was performed using an ECAT EXACT HR+ ncponc-2008-074f2.eps PET scanner (CTI PET Systems, Inc., Knoxville, TN, USA). The whole-body scan started at the patient's head and reached to his upper legs, and consisted of seven bed positions (7 min each). Each 7 min emission scan was followed by a 3 min transmission scan. A two-bed-position head scan immediately followed completion of the whole-body scan. Figure 1 111 In-oxine or Feridex® (Advanced Magnetics, Cambridge, MA, USA. Easy implementation, reduced whole-body radiation exposure (if radionuclide probes are used) and low signalto-background ratio are potential advantages of this technique as long as the cells do not release the probe inside the patient. Disadvantages are potential false-positive cell localization sites, lack of accurate information about cell survival, probe dilution resulting from cell division and a decrease in activity due to decay of radionuclide probes; consequently, this method is primarily a short-term monitoring technique. Another approach detects therapeutic cells by labeling them with a highly specific probe that binds to a receptor found only on their surface. This technique is not generally used because it could potentially require the development of specific imaging probes for every type of therapeutic cell. Even then, the sensitivity of this technique might be low. However, this approach does allow longterm monitoring and could potentially be used to study cell survival times.
Our study employed a reporter gene and probe-based imaging technique, which requires stable incorporation of a radionuclide-based or MRI reporter gene (regulated by a strong constitutively active promoter) into therapeutic cells before administration into patients. The reporter probe can then be injected at any time thereafter to image the location of therapeutic cells and to asses their survival; this technique could, therefore, provide a general solution for long-term monitoring of tailored therapeutic cells. Genetic modification of therapeutic cells without substantially affecting their characteristics could be a challenge. The sensitivity of this technique is determined by the reporter probe's pharmacokinetics and by the level at which the reporter gene is expressed in the cells.
We have investigated 18 F-FHBG in healthy human volunteers 5 and are now concurrently studying it in patients with glioma who have not undergone ACGT. We have also comprehensively assessed the safety of 18 F-FHBG in rats and rabbits. 6 Figure 2 illustrates two coronal slices of a control patient's whole-body 18 F-FHBG biodistribution PET image. The highest 18 F-FHBG activity can be observed in organs involved in its clearance such as the bladder, kidney, ureters, liver, gall bladder and intestines. 18 F-FHBG is cleared very rapidly from all other tissues. A sharp exponential decline of 18 F-FHBG activity is consistently observed in both patients' (a representative graph is included in Supplementary Data Set 2 online) and healthy human volunteers' 5 blood through time. 18 F-FHBG does not cross the blood-brain barrier; however, we did observe a slight increase in 18 F-FHBG background accumulation within intact glioma tumors or tumor resection sites of control patients included in this ACGT trial (controls were patients with glioma who did not receive CTLs), perhaps owing to a compromised blood-brain barrier. Quantitative analysis, however, shows greater than 2 × higher 18 F-FHBG accumulations in the resection site and intact tumor of the CTL-infused patient.
The patient described in this article received a total of approximately 1 × 10 9 CTLs within a 5-week period of direct infusions (with a 1-week break during week 3). These cells could either proliferate or die once injected into the patient. We were unable to quantify the number of CTLs present within the tumor resection site or the intact tumor near the corpus callosum. Such analysis would require a pharmacokinetic model 7 for 18 F-FHBG accumulation at brain tumor sites, and knowledge of average HSV1 tk expression levels per CTL at the time of imaging. We analyzed the level of HSV1 TK activity in the cultured CTLs that were injected into the patient by measuring the uptake of 3 H-labelled penciclovir by infused CTLs compared to control Jurkat cells (an immortalized T cell line), which did not express HSV1 tk. 8 Figure 3 shows that at 1 and 4 h after injection, levels of 3 H-labelled penciclovir in CTLs were approximately 3 × and 9 × respectively, higher than the levels in control cells. This low level of HSV1 TK activity explains why 18 F-FHBG accumulation in CTL infusion sites and intact tumors is only 2-3 × higher than background. In fact, during these uptake assays, cultured CTLs were exposed to an almost constant concentration of 18 F-FHBG, the equivalent of about 1 μCi/ml; whereas if 18 F-FHBG is homogeneously distributed across 6 l of blood, the maximum amount of labeled marker that CTLs would have been exposed to within the first 1-2 min after injection would have been about 1 μCi/ml. A rapid decline in blood concentration of 18 F-FHBG was observed within the first 20-40 min after its injection. Nonetheless, 18 F-FHBG enabled the detection of engineered CTLs because this marker was taken up at low background levels by the surrounding brain tissue, and because large numbers of CTLs were infused.
Several changes to the clinical protocol are planned for future patients. In subsequent clinical trials we will explore concomitant CTL infusion and IL-2 injection to prolong the survival of engineered CTLs and improve their therapeutic efficacy. We plan to improve imaging sensitivity by using a mutant HSV1 tk (HSV1 sr39tk), which should increase the rate of 18 F-FHBG accumulation by CTLs and yield a signal that is much greater than 2.5 × the background level. 9 Uptake into HSV1-tk-expressing CTLs from the patient Uptake into firefly-luciferaseexpressing CTLs in control Jurkat cells Figure 3 Uptake of 3 H-labelled penciclovir into the genetically engineered CTLs that were infused into the patient and into control Jurkat cells. The CTLs of the patient were genetically engineered to constitutively express HSV1 tk. The control cells expressed firefly luciferase rather than HSV1 tk. Uptake of 3 H-labelled penciclovir was 2.7 × higher at 1 h and 9.3 × higher at 4 h in the patient's CTLs than uptake into control cells, which had a fixed value at both time points. a Indicates a significant difference between uptake of 3 H-labelled penciclovir into patient CTLs versus control cells at 4 h (P < 0.001). Abbreviations: CTL, cytolytic T cell; HSV1 tk, herpes simplex virus 1 thymidine kinase gene.
www.nature.com/clinicalpractice/onc of accumulation in control patients. The FDA has now approved the use of two 18 F-FHBG PET scans per patient in future studies.
CONCLUSION
GBM is the most common malignant primary brain tumor. 10 The median survival for patients with GBM is around 12 months and very few patients survive more than 3 years after diagnosis. 10 ACGT is, therefore, a much needed treatment that should be investigated for its potential to extend survival for patients with GBM. Longterm imaging of therapeutic cells will be important for predicting the long-term efficacy of this type of treatment.
This case is the first ever documented study of reporter-gene-based imaging of therapeutic cells in a human patient, and also illustrates that 18 F-FHBG, which normally cannot cross the blood-brain barrier, can accumulate within glioma tumors. 18 F-FHBG should be able to detect therapeutic cells that express HSV1 tk within GBM tumors.
Supplementary information in the form of Data
Sets and a Timeline is available on the Nature Clinical Practice Oncology website.
